PPAR-delta activation ameliorates obesity and insulin resistance [59], and has been considered as a potential therapeutic target in treatment of lipid-related disorders, including dyslipidemia and diabetes [60, 61]. This evidence concerns the gene PPARD and diabetes mellitus.